Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.

doi:10.1136/gutjnl-2018-316023

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.

Gut - 1 Jan 2019

Zeissig Sebastian, Rosati Elisa, Dowds C Marie, Aden Konrad, Bethge Johannes, Schulte Berenice, Pan Wei Hung, Mishra Neha, Zuhayra Maaz, Marx Marlies, Paulsen Maren, Strigli Anne, Conrad Claudio, Schuldt Dörthe, Sinha Anupam, Ebsen Henriette, Kornell Sabin-Christin, Nikolaus Susanna, Arlt Alexander, Kabelitz Dieter, Ellrichmann Mark, Lützen Ulf, Rosenstiel Philip C, Franke Andre, Schreiber Stefan

Abstract excerpt

OBJECTIVE: Vedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved for the treatment of Crohn's disease and ulcerative colitis. The efficacy of vedolizumab has been suggested to result from inhibition of intestinal T cell trafficking although human data to support this conclusion are scarce. We therefore performed a comprehensive analysis of vedolizumab-induced alterations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptive Immunity

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Gastrointestinal Agents

Share to Inflammatory Bowel Diseases

Share to Infliximab

Share to Integrins

Share to Sequence Analysis, RNA

Share to Tomography, Emission-Computed, Single-Photon

Source

Open in PubMed

Identifiers

PMID: 29730603
DOI: 10.1136/gutjnl-2018-316023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.PMID 29730603Read ↗

Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.Semantic proximity Read ↗

Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7-Blocking Therapy in Inflammatory Bowel Disease.Semantic proximity Read ↗

Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitisSemantic proximity Read ↗

Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitisSemantic proximity Read ↗

High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitisSemantic proximity Read ↗

Downregulated Interferon Signalling in T Cells is Associated with Response to Vedolizumab in Inflammatory Bowel DiseaseSemantic proximity Read ↗

Residual homing of α4β7-expressing β1 + PI16 + regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumabSemantic proximity Read ↗

Single-cell characterization of peripheral blood mononuclear cells from vedolizumab-treated patients with Crohn's disease identifies response-associated differences among the plasmacytoid dendritic cell and classical monocyte populations.Semantic proximity Read ↗

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel DiseaseSemantic proximity Read ↗

A mutation that blocks integrin α4β7 activation prevents adaptive immune-mediated colitis without increasing susceptibility to innate colitis.Semantic proximity Read ↗

Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel DiseaseSemantic proximity Read ↗

Exhaustion of CD39-Expressing CD8+ T Cells in Crohn’s Disease Is Linked to Clinical OutcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.